Primary Premature Ejaculation Genetics
Primary Premature Ejaculation Genetics
The main objective of our study is to identify the first genetic etiology of primary
 Premature Ejaculation (PE). We will test and evaluate the existence of genetic determinism
 conferring susceptibility to a life-long syndrome (primary premature ejaculation) in some
 patients. To this end, we plan to establish a collection of biological samples and a database
 of patients with this extreme syndrome, which we will analyze by Genome Wide analysis. This
 will lead to improvements in the biological understanding, the "knowledge" of physicians of
 the disease, and should improve the patients' quality of life. Not all PE cases have the same
 physiopathology and treatment efficiency, which depend on the specific mechanism involved in
 the clinical context. Our work will make it possible to develop new therapeutic approaches
 suitable for a large proportion of individuals presenting PE. This integrative approach
 combining researchers, patients and ethics committees will facilitate profound reflection,
 promoting the creation of suitable structures capable of receiving patients for appropriate
 consultations. This unique study of PE should also favor industrial partnerships.
2.1 Main Objective

 -  To identify the molecular basis of primary premature ejaculation (PPE) in humans for the
 development of new adapted therapy.

 -  Check and confirm the genetic hypothesis of PPE to fill the void of genetic knowledge
 about this syndrome.

 -  Improve knowledge of physicians on this disease to increase the comfort of life of
 patients.

 2.2 Secondary Objectives

 -  Provide the basis for new therapeutic approaches.

 -  Expanded knowledge of the aetiology of PE and allow better management of patients.

 -  Develop strategies to prevent the consequences, sometimes severe , of this condition on
 the intimate, personal, social and professional life of these patients. Because all the
 PE do not have the same pathophysiology and treatment success depends on its relevance
 to the specific mechanism of the clinical form concerned.

 -  Increase the comfort of life of the patients.

 -  Eliminate public prejudice based on misconceptions.
Inclusion Criteria:

 1. . Patients (index cases ) Prospective and retrospective cases

 -  Man aged over 18 years

 -  signing the informed consent

 -  Presenting primary PE

 -  have an affiliation to a social security system

 2. . Related

 -  Male or female over 18 years

 -  be related to the index case

 -  signing the informed consent

 -  have an affiliation to a social security system

 Non Inclusion Criteria:

 1. . Patients ( index case ) :

 -  Be aged under 18

 -  have known genetic variations that predispose or can promote psychological
 disorders that can lead to PE ( eg: Kallman 's Syndrome , micropenis , testicular
 dysgenesis , Klinfelter syndrome, Leydig cell hypoplasia )

 -  have had psycho- social and psycho- traumatic factors in childhood

 -  Inability to receive clear information on the protocol

 -  Person deprived of liberty by judicial or administrative decision

 -  Major Person subject of legal protection or unable to consent

 -  Refusal to be informed of an abnormality detected after genetic testing

 -  History of allergies to lidocaine or other anesthetic agent used during puncture
 or blood sample

 2. . Related :

 -  Age <18 years

 -  Inability to receive clear information about the protocol . Unable to participate
 in the entire study.

 -  No coverage by the social security system

 -  Absence of signature of consent or refusal of the related party

 -  Person deprived of liberty by judicial or administrative decision

 -  Major Person subject of legal protection or unable to consent

 -  Refusal to be informed of a genetic abnormality detected

 -  History of allergies to lidocaine or other anesthetic agent used during puncture
 or blood sample